In a phase II trial (NCT02789332), it was found that individuals with primary HER2 − breast cancer and homologous recombination deficiency responded better to olaparib than carboplatinum as neoadjuvant with paclitaxel in terms of pathological complete response percentage, followed by epirubicin/cyclophosphamide chemotherapy [51]. This evidence concerns the gene ERBB2 and breast cancer.